Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma

Background and Objectives: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is one of the standard-of-care therapies in patients with EGFR-mutant lung adenocarcinoma; however, acquired resistance inevitably developed. Despite the proposition of histological tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Po-Hsin, Huang, Yen-Hsiang, Lin, Ho, Hsu, Kuo-Hsuan, Chen, Kun-Chieh, Tseng, Jeng-Sen, Chang, Gee-Chen, Yang, Tsung-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323036/
https://www.ncbi.nlm.nih.gov/pubmed/35888627
http://dx.doi.org/10.3390/medicina58070908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323036/
https://www.ncbi.nlm.nih.gov/pubmed/35888627
http://dx.doi.org/10.3390/medicina58070908

Ejemplares similares